doi: 10.1002/1097-0142(197405)33:5<1219::aid-cncr2820330505>3.0.co;2-u.
Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors
- PMID: 4856724
- DOI: 10.1002/1097-0142(197405)33:5<1219::aid-cncr2820330505>3.0.co;2-u
Item in Clipboard
Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors
Cancer.
1974 May.
No abstract available
Similar articles
-
Diamminodichloroplatinum in the chemotherapy of testicular tumors.J Urol. 1974 Jul;112(1):100-4. doi: 10.1016/s0022-5347(17)59652-4. J Urol. 1974. PMID: 4858106 No abstract available.
-
Cisplatin as adjunctive treatment for invasive bladder carcinoma: tolerance and toxicities.Urology. 1984 Apr;23(4 Suppl):110-7. doi: 10.1016/s0090-4295(84)80080-1. Urology. 1984. PMID: 6538712 Clinical Trial. No abstract available.
-
The treatment of metastatic testicular tumors.J Urol. 1972 Sep;108(3):439-42. doi: 10.1016/s0022-5347(17)60765-1. J Urol. 1972. PMID: 4115279 No abstract available.
-
Cancer of the testis: a new paradigm.Hosp Pract (Off Ed). 1986 Apr 15;21(4):165-72, 175-8. Hosp Pract (Off Ed). 1986. PMID: 2420812 Review. No abstract available.
-
Cis-diamminedichloroplatinum (II). A new anticancer drug.Ann Intern Med. 1977 Jun;86(6):803-12. doi: 10.7326/0003-4819-86-6-803. Ann Intern Med. 1977. PMID: 326117 Review.
Cited by
-
Regulator of G protein signaling 17 represents a novel target for treating cisplatin induced hearing loss.Sci Rep. 2021 Apr 14;11(1):8116. doi: 10.1038/s41598-021-87387-5. Sci Rep. 2021. PMID: 33854102 Free PMC article.
-
Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma.Cancer Chemother Pharmacol. 1982;8(3):281-4. doi: 10.1007/BF00254051. Cancer Chemother Pharmacol. 1982. PMID: 6127169
-
Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).Cancer Chemother Pharmacol. 1988;22(3):228-34. doi: 10.1007/BF00273416. Cancer Chemother Pharmacol. 1988. PMID: 3044631
-
Platinum neurotoxicity pharmacogenetics.Mol Cancer Ther. 2009 Jan;8(1):10-6. doi: 10.1158/1535-7163.MCT-08-0840. Mol Cancer Ther. 2009. PMID: 19139108 Free PMC article. Review.
-
Optimal drug therapy in the treatment of testicular cancer.Drugs. 1991 Jul;42(1):52-64. doi: 10.2165/00003495-199142010-00004. Drugs. 1991. PMID: 1718685 Review.